The letters  before and after the numbers represent the single nucleotides that make up the DNA sequence and codons to code for an amino acid (A = adenine, C = cytosine, G = guanine, T = thymine). Amino acids represented:(C = cysteine, G = glycine, K = lysine, P = proline, R = arginine, S = serine, T = threonine, V = valine). NR = not reported.

References:

1. Gough AC, Smith C A, Howell S M et al. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.  Genomics 1993;15:430-432.  PubMed
2. Kimura S, Umeno M, Skoda R C et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.  Am J Hum Genet 1989;45:889-904.  PubMed   
3. Griese EU, Asante-Poku S, Ofori-Adjei D et al.  Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.  Pharmacogenetics 1999;9:715-23.  PubMed
4. Kubota T, Yamaura Y, Ohkawa N et al.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.  Br J Clin Pharmacol  2000;50:31-4.  PubMed
5. Johansson I, Lundqvist E, Bertilsson L et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.  Proc Nat Acad Sci 1993;90:11825-11829.  PubMed
6. Gough AC, Miles JS, Spurr NK et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.  Nature 1990;347:773-776.  PubMed
7. Hanioka N, Kimura S, Meyer UA et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G(1934)-to-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3-prime splice recognition site.  Am J Hum Genet. 1990;47:994-1001.  PubMed
8. Gaedigk A, Blum M, Gaedigk R et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.  Am J Hum Genet 1991;48:943-950.  PubMed
9. Nelson DR, Koymans L, Kamataki T et al. Cytochrome P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature.  Pharmacogenetics 1996;6:1-42.  PubMed
10. Steen VM, Molven A, Aarskog NK et al.  Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene.  Hum Molec Genet  1995;4:2251-2257.  PubMed
11. Saxena R, Shaw GL, Relling MV et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.  Hum Molec Genet 1994;3:923-926.  PubMed
12. Tyndale R, Aoyama T, Broly F et al.  Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.  Pharmacogenetics 1991;1:26-32.  PubMed
13. Kagimoto M, Heim M, Kagimoto K et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: study of the functional significance of individual mutations by expression of chimeric genes.  J Biol Chem 1990;265:17209-17214.  PubMed
14. Wang SL, Lai MD, Huang JD.  G169R mutation diminishes the metabolic activity of CYP2D6 in chinese.  Drug Metab Dispos 1999;27:385-8.  PubMed
15. Masimirembwa C, Persson I, Bertilsson L et al.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.  Br J Clin Pharmacol  1996;42:713-9.  PubMed
16. Wennerholm A, Johansson I, Hidestrand M et al.  Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.  Pharmacogenetics  2001;11:417-27.  PubMed
17. Ikenaga Y, Fukuda T, Fukuda K et al.  The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.  Drug Metab Pharmacokinet 2005;20:113-6.  PubMed
18. Raimundo S, Toscano C, Klein K et al.  A novel intronic mutation, 2988G>A, with predictivity for impaired function of cytochrome P450 2D6 in white subjects.  Clin Pharmacol Ther  2004;76:128-38.  PubMed

Editors:  Anthony J. Busti, MD, PharmD, FNLA, FAHA
Last Reviewed:  June 2015

• Pharmacogenetics: CYP1A2 Genetic Polymorphisms Reference Table
• Pharmacogenetics: CYP2C9 Genetic Polymorphisms Reference Table
• Pharmacogenetics: CYP2C19 Genetic Polymorphisms Reference Table
• Pharmacogenetics: CYP3A4 Genetic Polymorphisms Reference Table